Literature DB >> 33504264

The Use of the Bethesda System for Reporting Thyroid Cytopathology in Pediatric Thyroid Nodules: A Meta-Analysis.

Huy Gia Vuong1,2, Duy Giang Bao Chung3, Luan Minh Ngo3, Thien Quoc Bui4, Lewis Hassell1, Chan Kwon Jung5, Kennichi Kakudo6, Andrey Bychkov7,8.   

Abstract

Background: Little is known about the application of the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) in pediatric thyroid nodules. This meta-analysis was aimed to investigate the use of TBSRTC in the pediatric population.
Methods: Relevant articles were searched in PubMed and Web of Science. Meta-analysis of proportion and its 95% confidence interval (CI) were computed utilizing the random-effect model. We used subgroup analyses and meta-regression to explore the sources of heterogeneities. Egger's regression test and funnel plot visualization were used to examine publication bias.
Results: We included 17 articles comprising of 3687 pediatric thyroid nodules for meta-analyses. TBSRTC outputs including frequency and risk of malignancy (ROM) for the majority of categories were not statistically different from recently published meta-analysis of 145,066 thyroid nodules in adult patients. The resection rate (RR) in the pediatric group was significantly higher in most of the categories compared with published adult data: benign, 23.2% [CI = 18.6-27.9] vs. 13.0% [CI = 9.5-16.5]; atypia of undetermined significance/follicular lesion of undetermined significance, 62.6% [CI = 50.3-74.9] vs. 36.2% [CI = 29.9-42.5]; follicular neoplasm/suspicious for follicular neoplasm, 84.3% [CI = 75.2-93.4] vs. 60.5% [CI = 54.5-66.5]; and suspicious for malignancy, 93.8% [CI = 90.1-97.6] vs. 69.7% [CI = 64.0-75.5].
Conclusion: TBSRTC is a valuable tool to make clinical decisions for pediatric patients with thyroid nodules. Pediatric patients with benign and indeterminate thyroid nodules had a higher RR than adult counterpart, but ROM of these categories in adults and children was not statistically different suggesting a potential risk of overtreatment in pediatric patients. Determining the best treatment guidelines and additional tools for risk stratification must be a top priority to precisely identify the target patient groups for surgical intervention.

Entities:  

Keywords:  FNA; TBSRTC; pediatric; resection rate; risk of malignancy; thyroid

Mesh:

Year:  2021        PMID: 33504264     DOI: 10.1089/thy.2020.0702

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  5 in total

1.  A Matched-Pair Analysis of Nuclear Morphologic Features Between Core Needle Biopsy and Surgical Specimen in Thyroid Tumors Using a Deep Learning Model.

Authors:  Faridul Haq; Andrey Bychkov; Chan Kwon Jung
Journal:  Endocr Pathol       Date:  2022-10-14       Impact factor: 4.056

Review 2.  Emerging Biomarkers in Thyroid Practice and Research.

Authors:  Shipra Agarwal; Andrey Bychkov; Chan-Kwon Jung
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

3.  Diagnostic Performance of Thyroid Core Needle Biopsy Using the Revised Reporting System: Comparison with Fine Needle Aspiration Cytology.

Authors:  Kwangsoon Kim; Ja Seong Bae; Jeong Soo Kim; So Lyung Jung; Chan Kwon Jung
Journal:  Endocrinol Metab (Seoul)       Date:  2022-02-28

4.  Paediatric differentiated thyroid carcinoma: a UK National Clinical Practice Consensus Guideline.

Authors:  Sasha R Howard; Sarah Freeston; Barney Harrison; Louise Izatt; Sonali Natu; Kate Newbold; Sabine Pomplun; Helen A Spoudeas; Sophie Wilne; Tom R Kurzawinski; Mark N Gaze
Journal:  Endocr Relat Cancer       Date:  2022-09-07       Impact factor: 5.900

5.  Predictive factors of malignancy in pediatric patients with thyroid nodules and performance of the Italian classification (SIAPEC 2014) in the outcome of the cytological FNA categories.

Authors:  Gerdi Tuli; Jessica Munarin; Erica Agosto; Patrizia Matarazzo; Francesco Quaglino; Alberto Mormile; Luisa de Sanctis
Journal:  Endocrine       Date:  2021-06-14       Impact factor: 3.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.